Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS
15 patients around the world
Available in Argentina, Mexico
Multiple Sclerosis (MS) can be a devastating disease. There is evidence that mesenchymal stem
cell treatment is safe and efficacious for the treatment of MS. Patients with MS will receive
a single intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal
stem cells. The dose for the infusion will be 100 million cells. Patients will be evaluated
within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for
safety and efficacy.
For patients with more severe disease requiring chemotherapeutic drugs such as methotrexate,
an autologous T Cell vaccine will be utilized created from the patient's own T cells obtained
by apheresis
The Foundation for Orthopaedics and Regenerative Medicine